Mobile Site ›
Print Page E-mail Page

Circulating Tumor Cells and the CellSearch Assay



Subscribe

Receive notification when new Hot Topics are published:

Progression-Free Survival in MBC

Slide 14

April 2011

Kaplan-Meier analyses were performed to determine whether circulating tumor cell counts could predict progression-free survival. Patients were separated into 2 groups based on their circulating tumor cell count. The graph on the left shows the results of baseline circulating tumor cell counts. The favorable group represented patients with a baseline circulating tumor cell count <5, while the unfavorable group represented patients with a baseline count =5. The median progression-free survival was approximately 7.0 months for the favorable group and 2.7 months for the unfavorable group, which was statistically significant.

The graph on the right shows the value of monitoring circulating tumor cell levels during the course of treatment. The most striking results show that patients with =5 circulating tumor cells at both baseline and at the end of treatment had significantly shorter median progression-free survival (1.8 months) than patients in all other groups. Patients with <5 circulating tumor cells at each time point had the longest median progression-free (7.2 months). Interestingly, patients with =5 circulating tumor cells at baseline, which decreased to <5 at the end of treatment had significantly longer median progression-free survival than patients who maintained counts of at least 5 at both time points, 6.1 months versus 1.8 months.

Progression-Free Survival in MBC

 


Jump to section:

Key